Are you above the legal age to view this content in your province/state?

Home / Industry News / FSD Pharma Inc generates $7.7M in proceeds through sale of interest in Cannara Biotech

FSD Pharma Inc generates $7.7M in proceeds through sale of interest in Cannara Biotech

FSD Pharma Inc generates $7.7M in proceeds through sale of interest in Cannara Biotech

The share sale transaction represents a whopping 670% return on investment

CEO Raza Bokhari said FSD Pharma shareholders recognize a 7x return in less than two years through the ‘positive milestone’

FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE), a specialty pharmaceutical research company focused on cannabinoids, said Thursday that it had sold its 12% equity interest in Cannara Biotech Inc (CSE:LOVE) to a consortium of buyers for cash proceeds of more than $7.7 million. 

In a statement, the Canadian company said the share sale transaction was negotiated at arm’s length with buyers that included entities controlled by members of the Cannara board and senior management. 

A substantial portion of FSD Pharma’s shareholdings in Cannara was subject to a statutory escrow expiring on December 2021. Under the terms of deal, the buyers agreed to acquire FSD Pharma’s interest subject to escrow and, as such, assumed all of the associated market risk.

The share sale transaction represents a 670% return on the company’s stake in Cannara, noted the company.

“This is a very positive milestone for the shareholders and stakeholders of FSD Pharma to recognize a 7x return in less than two years,” FSD Pharma CEO Raza Bokhari said in a statement.

Bokhari said the transaction hopefully represents “the first of others” that will follow to strengthen the company’s cash position on the balance sheet.

“Our aim is to scale up to $50 million in disposable cash through monetizing our non-cash assets and raising new capital from institutional and institutional grade investors in the United States and elsewhere,” said Bokhari.

FSD Pharma is focused on the research and development of cannabinoid-based treatments for several central nervous system disorders, including fibromyalgia, and irritable bowel syndrome.

Headquartered at the former Kraft plant in Cobourg, Ontario, with large expansion potential, FSD also grows medical-grade cannabis at its 25,000 square foot facility in Ontario.

Through its wholly-owned subsidiary FV Pharma Inc, the group is a licensed producer under Canada’s Cannabis Act, having received its cultivation license in October 2017 and its sale for medical purposes license in April 2019. 

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

A U.S. Marijuana Stock Versus a Canadian Marijuana Stock

A U.S. Marijuana Stock Versus a Canadian Marijuana Stock

Which of These Pot Stocks to Watch is Showing the Most Momentum? U.S., September 10, …